Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CBFB | Q13951 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 3/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14892479 | 0.86 | SMN1; SMN2 (0.53) | KCNH2BRD4TERTNPC1RAB9A | |
| SCHEMBL12944362 | 0.85 | CBFB (0.44) | CBFBBRD4TERTNPBWR1PDE3B | |
| SCHEMBL126325 | 0.85 | CBFB (0.52) | CBFBNPC1RAB9AAURKAFGFR1 | |
| SCHEMBL14892249 | 0.83 | TOP1 (0.41) | KCNH2CBFBBRD4TERTMAOB | |
| SCHEMBL26158811 | 0.81 | METAP2 (0.52) | CBFBMETAP2METAP1NPC1PKM | |
| SCHEMBL125111 | 0.80 | CBFB (0.67) | CBFBMETAP2METAP1NPC1PKM | |
| SCHEMBL125213 | 0.80 | CBFB (0.46) | CBFBFGFR1 | |
| SCHEMBL125289 | 0.79 | CBFB (0.65) | CBFBMETAP2METAP1NPC1PKM | |
| SCHEMBL18163934 | 0.78 | PRKAG1 (0.41) | KCNH2BRD4TERTNPC1RAB9A | |
| SCHEMBL24347820 | 0.77 | NPBWR1 (0.55) | KCNH2NPC1RAB9ASIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | KCNH2 3266/4885CBFB 3/4885BRD4 512/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | KCNH2 3151/4885CBFB 3/4885BRD4 512/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | KCNH2 3151/4885CBFB 3/4885BRD4 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.